Join
Live feed
·
INSIDERFilingvia Quantisnow
Soleno Therapeutics Inc. logo

Sr. VP of Clinical Development Huang Michael F. was granted 6,400 shares, increasing direct ownership by 18% to 41,400 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
SLNO· Soleno Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SLNO (Soleno Therapeutics Inc.) and more on Quantisnow.